Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

1. Subbiah, V.
2. Hu, M.I.
3. Wirth, L.J.
4. Schuler, M.
5. Mansfield, A.S.
6. Curigliano, G.
7. Brose, M.S.
8. Zhu, V.W.
9. Leboulleux, S.
10. Bowles, D.W.
11. Baik, C.S.
12. Adkins, D.
13. Keam, B.
14. Matos, I.
15. Garralda, E.
16. Gainor, J.F.
17. Lopes, G.
18. Lin, C.-C.
19. Godbert, Y.
20. Sarker, D.
21. Miller, S.G.
22. Clifford, C.
23. Zhang, H.
24. Turner, C.D.
25. Taylor, M.H.